Chemistry:AVN-322
From HandWiki
| |
| Names | |
|---|---|
| IUPAC name
5-(benzenesulfonyl)-N,11-dimethyl-2,3,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7-tetraen-4-amine;hydrochloride
| |
| Other names
List
| |
| Identifiers | |
| ChemSpider | |
PubChem CID
|
|
| UNII | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
AVN-322 is a 5-hydroxytryptamine subtype 6 receptor antagonist manufactured by Avineuro Pharmaceuticals Inc. that could potentially be used to combat Alzheimer's disease and schizophrenia.[2][3] AVN-322 also reverses the negative effects of scopolamine and MK-80.[3]
The compound is a sister drug to AVN-101 and AVN-211, two similar compounds under trial for treating Alzheimer's.[3] Phase I trials for the drug were initiated in 2009 by Avineuro, and completed in the spring of 2010.[4][5] The trials showed that AVN-322 was tolerated in a range of doses without any adverse effects, and Avineuro released plans to commence Phase II trials later the same year.[5] The plan for further trials was discontinued in 2013.[6]
References
- ↑ National Center for Biotechnology Information. "Compound Summary for CID 135905417, B7DM6S48B2" PubChem. Accessed 12 March 2023.
- ↑ "AVN-322 | CAS#1194574-68-9 | CAS#1194574-33-8 | 5-HT6 Antagonist | MedKoo". https://www.medkoo.com/products/12765.
- ↑ 3.0 3.1 3.2 Andrews, Megan; Tousi, Babak; Sabbagh, Marwan N. (2018-06-01). "5HT6 Antagonists in the Treatment of Alzheimer's Dementia: Current Progress" (in en). Neurology and Therapy 7 (1): 51–58. doi:10.1007/s40120-018-0095-y. ISSN 2193-6536. PMID 29728891. PMC 5990506. https://doi.org/10.1007/s40120-018-0095-y.
- ↑ "Avineuro Announces Beginning Of Phase I Clinical Studies Of AVN-322, Potent Small Molecule For Treatment Of Alzheimer's Disease" (in en-US). https://www.biospace.com/article/avineuro-announces-beginning-of-phase-i-clinical-studies-of-avn-322-potent-small-molecule-for-treatment-of-alzheimer-s-disease-/.
- ↑ 5.0 5.1 "Avineuro Reports Positive Phase I Clinical Trial Results On AVN-322, Potent Small Molecule For Treatment Of Alzheimer's Disease" (in en-US). https://www.biospace.com/article/avineuro-reports-positive-phase-i-clinical-trial-results-on-avn-322-potent-small-molecule-for-treatment-of-alzheimer-s-disease-/.
- ↑ "Phase II trial of AVN 322 in patients with Alzheimer's disease. - AdisInsight". https://adisinsight.springer.com/trials/700053427.
 |  |
